Moody Aldrich Partners’s Kyntra Bio KYNB Stock Holding History

Moody Aldrich Partners’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,256	Closed	-$1.96M	–	180
2021 Q1	$1.96M	Buy	2,256 +33	+1%	+$35.1K	0.28%	94
2020 Q4	$2.06M	Buy	2,223 +2	+0.1%	+$2.1K	0.33%	91
2020 Q3	$2.28M	Buy	2,221 +61	+3%	+$65.6K	0.48%	86
2020 Q2	$2.19M	Buy	2,160 +305	+16%	+$283K	0.47%	81
2020 Q1	$1.61M	Buy	+1,855	New	+$1.84M	0.49%	76
2018 Q4	–	Sell	-1,353	Closed	-$2.06M	–	101
2018 Q3	$2.06M	Buy	1,353 +209	+18%	+$322K	0.59%	77
2018 Q2	$1.79M	Buy	1,144 +84	+8%	+$110K	0.64%	72
2018 Q1	$1.22M	Buy	1,060 +249	+31%	+$328K	0.79%	66
2017 Q4	$961K	Buy	811 +169	+26%	+$212K	0.78%	64
2017 Q3	$864K	Buy	642 +85	+15%	+$89.6K	0.89%	54
2017 Q2	$450K	Buy	+557	New	+$388K	0.56%	81

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Moody Aldrich Partners's KYNB Position: Q2 2021 in Review

Moody Aldrich Partners sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 2,256 shares — an estimated $1.96M sold.

Moody Aldrich Partners first reported a position in KYNB in Q2 2017 and held it in 11 quarters. The position peaked at $2.28M in Q3 2020. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

Moody Aldrich Partners reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
Moody Aldrich Partners sold 2,256 Kyntra Bio shares in Q2 2021, an estimated $1.96M.
Moody Aldrich Partners first reported a position in Kyntra Bio in Q2 2017 and held it in 11 quarters.
Moody Aldrich Partners's Kyntra Bio position peaked at $2.28M in Q3 2020.
174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on Moody Aldrich Partners's 13F filing for Q2 2021, filed 4 Aug 2021.